论文部分内容阅读
目的：评价吉西他滨诱导化疗后放疗同步联合替吉奥治疗老年局部进展期胰腺癌（LAPC）的安全性及疗效。方法对38例老年局部进展期胰腺癌用吉西他滨诱导化疗7周，每周1次，每次1000 mg／m2，休息1周后开始放疗同步联合替吉奥化疗，替吉奥剂量为40－80 mg／m2．d，2次／d，5 d／周；放疗采用常规分割2．0 Gy／次，中位照射剂量51Gy（34～64 Gy）。结果临床受益反应（CBR）19例，占50％；近期疗效：完全缓解（CR）0例，部分缓解（PR）6例，稳定（SD）24例，进展（PD）4例，中位生存时间10个月（4～25个月）；1年、2年生存率分别是39．5％和18．4％。骨髓抑制1～2级16例，3级以上4例；胃肠道不良反应1～2级20例，3级以上4例。结论吉西他滨诱导化疗后再放化联合治疗局部进展期胰腺癌疗效较好，不良反应可耐受。“,”objective To evaluate the safety and ef icacy of induction chemotherapy with gemcitabine fol owed by concurrent chemoradiotherapy with tegafur in old patients with local y ad-vanced pancreatic cancer(LAPC).Methods A total of 38 patients with local y advanced pancreatic cancer were enrol ed.Al patients received seven cycles of induction chemotherapy of gemcit-abine1000mg/m2,onceaweek.Concurrentchemoradiotherapybegan1weekaftercompletionofinductionchemotherapy.Radiotherapywasdeliveredwithamediandoseof51Gy(34~64Gy) with 2.0 Gy in a fraction.The radiotherapy was combined with tegafur at a dosage of 40-80 mg/m2.d,twice daily,every two weeks.Results Twenty patients(50%)were evaluated as clinical benefit response(CBR).0 cases were observed with complete remission(CR),6 with partial remission(PR),24 with stable disease(SD),and 4 with progressive disease(PD).The median over-al survival was 10 months(range of 4—25 months).The 1 -、2-year overal survival rate was 39.5%and 18.4%.respectively.Myelosuppression was recorded in 16 patients with grades 1 ~2, and 4 patients with grade 3.20 patients suf ered from grade 1 ~2 gastrointestinal toxicities,while 4 patients suf ered from grade 3.Conclusions The preliminary results showed that induction chem-otherapy with gemcitabine fol owed by concurrent chemoradiotherapy with tegafur in patients with old LAPC might achieve encouraging ef icacy with bet er tolerance.